ReviewNaunyn-Schmiedeberg's archives of pharmacology2008
The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 97 citations in OpenAlex.
- Article
- Is the βBiomolecules · 2023Review
- Thermogenic Brown Fat in Humans: Implications in Energy Homeostasis, Obesity and Metabolic Disorders.The world journal of men's health · 2023Review
- Leptin-A Potential Bridge between Fat Metabolism and the Brain's Vulnerability to Neuropsychiatric Disorders: A Systematic Review.Journal of clinical medicine · 2021Review
- Leanness and Low Plasma Leptin in GPR17 Knockout Mice Are Dependent on Strain and Associated With Increased Energy Intake That Is Not Suppressed by Exogenous Leptin.Frontiers in endocrinology · 2021Article
- Inactivity and Skeletal Muscle Metabolism: A Vicious Cycle in Old Age.International journal of molecular sciences · 2020Review
- Vasculature-associated fat macrophages readily adapt to inflammatory and metabolic challenges.The Journal of experimental medicine · 2019Article
- The role of αJournal of receptor and signal transduction research · 2017Article
- Relationship of brown adipose tissue perfusion and function: a study through β2-adrenoreceptor stimulation.Journal of applied physiology (Bethesda, Md. : 1985) · 2016Article
- Pharmacological Activation of Thyroid Hormone Receptors Elicits a Functional Conversion of White to Brown Fat.Cell reports · 2015Article
- Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention.Journal of clinical medicine · 2015Review
- Of mice and men: novel insights regarding constitutive and recruitable brown adipocytes.International journal of obesity supplements · 2015Review
- Npvf: Hypothalamic Biomarker of Ambient Temperature Independent of Nutritional Status.PLoS genetics · 2015Article
- Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity.Frontiers in endocrinology · 2015Review
- Adipose tissue plasticity from WAT to BAT and in between.Biochimica et biophysica acta · 2014Review
- Brown adipose tissue: endocrine determinants of function and therapeutic manipulation as a novel treatment strategy for obesity.BMC obesity · 2014Review
- Translational issues in targeting brown adipose tissue thermogenesis for human obesity management.Annals of the New York Academy of Sciences · 2013Review
- Brown adipose tissue: development, metabolism and beyond.The Biochemical journal · 2013Review
- Human adipose dynamics and metabolic health.Annals of the New York Academy of Sciences · 2013Review
- Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although beta3-adrenoceptor (beta3AR) agonists have not become drugs for the treatment of obesity or diabetes, they offer perspectives on obesity drug discovery, the physiology of energy expenditure and receptor pharmacology. beta3AR agonists, some of which also stimulate other betaARs in humans, selectively stimulate fat oxidation in rodents and humans. This appears to be why they improve insulin sensitivity and reduce body fat whilst preserving lean body mass. Regulatory authorities ask that novel anti-obesity drugs improve insulin sensitivity and reduce mainly body fat. Drugs that act on different targets to stimulate fat oxidation may also offer these benefits. Stimulation of energy expenditure may be easy to detect only when the sympathetic nervous system is activated. Leptin resembles beta3AR agonists in that it increases fat oxidation, energy expenditure and insulin sensitivity. This is partly because it raises sympathetic activity, but it may also promote fat oxidation by directly stimulating muscle leptin receptors. The beta1AR and beta2AR can, like the beta3AR, display atypical pharmacologies. Moreover, the beta3AR can display variable pharmacologies of its own, depending on the radioligand used in binding studies or the functional response measured. Studies on the beta3AR demonstrate both the difficulties of predicting the in vivo effects of agonist drugs from in vitro data and that there may be opportunities for identifying drugs that act at a single receptor but have different profiles in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.